Dieses Ergebnis aus Springer Nature Journals kann Gästen nicht angezeigt werden. Login für vollen Zugriff.

CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial

Title:	CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
Authors:	DiPersio, John F.^{Aff1, IDs41591026043621_cor1}; Koehne, Guenther^Aff2; Shah, Nirali N.^Aff3; Bernard, Léa^Aff4; Suh, Hyung C.^Aff5; Koura, Divya^Aff6; Tamari, Roni^Aff7; Mushtaq, Muhammad Umair^Aff8; Maakaron, Joseph^Aff9; Rimando, Joseph^Aff10; Kennedy, Vanessa E.^Aff11; Patel, Sagar S.^Aff12; Hudson, Chad^Aff13; Loken, Michael R.^Aff13; Slapak, Christopher A.^Aff14; Lloyd, Deborah M.^Aff14; Stanizzi, Darren A.^Aff14; Lee-Sundlov, Melissa M.^Aff14; Thosar, Sanjana^Aff14; Mundelboim, Guy^Aff14; Guo, Guangwu^Aff14; Ge, Huanying Gary^Aff14; Li, Bin E.^Aff14; Xavier-Ferrucio, Juliana^Aff14; Hyzy, Sharon L.^Aff14; Lin, Michelle I.^Aff14; Raffel, Glen D.^Aff14; Cooper, Brenda W.^Aff15
Source:	Nature Medicine. 32(5):1763-1772
Database:	Springer Nature Journals